Calquence approved in China for chronic lymphocytic leukaemia
Approval based on results from ASCEND global Phase III trial and a Phase I/II local trial, which showed 83.3% overall response rate in Chinese patients treated with Calquence. AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy. The approval by the National Medical Products Administration (NMPA) was based on positive results from two clinical